The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD)
Most cases of alleged bevacizumab-induced ILD are seen with combination chemotherapy including bevacizuma. All emanate from Japan at the present time. Evidence is low unless cases emerge from the west also. We follow-up
Publications
Tamura S, Kusaba H, Kubo N, Ijichi K, Tsuchihashi K, Komoda M, Uchino K, Ariyama H, Akashi K, Baba E
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
Medical oncology (Northwood, London, England) 2014 Mar;31;856 — 2014 Mar — 856
Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
Japanese journal of clinical oncology 2011 Apr;41;498-502 — 2011 Apr — 498-502